Hookipa Pharma Inc. Reports Q2 2023 Net Loss of $18.0 Million
Company Generates $2.7 Million in Revenue from Collaboration and Licensing During Second Quarter
Hookipa Pharma Inc.(HOOK), a clinical-stage biopharmac eutical company focused on developing novel immunotherapies for infectious diseases and cancers, has released its unaudited financial results for the second quarter of 2023. The company reported a net loss of $18.0 million for the quarter, while generating $2.7 million in revenue from collaboration and licensing activities. The financial statements reveal insights into Hookipa Pharma's balance sheet, operations, and stockholders' equity.
Net Loss and Financial Position
Hookipa Pharma's financial report for the second quarter of 2023 indicates a net loss of $18.0 million. This loss reflects the company's investments in research and development as well as general and administrative expenses. Despite the loss, Hookipa Pharma remains committed to advancing its innovative immunotherapies and expanding its product pipeline.
Revenue from Collaboration and Licensing
